Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma

Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma

Abstract Therapeutic strategies for advanced renal cell carcinoma have advanced dramatically since the approval of immune checkpoint inhibitors. To date, four PD-L1 assays have been established as companion diagnostic tools for checkpoint inhibitors. However, all PD-L1 assays present several limitat...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoko Koh, Taigo Kato, Gaku Yamamichi, Eisuke Tomiyama, Makoto Matsushita, Koji Hatano, Atsunari Kawashima, Norio Nonomura, Motohide Uemura
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Clear cell renal cell carcinoma
Programed death-ligand 1 (PD-L1)
Immunohistochemistry
Next-generation sequencing
Companion diagnostics
Online Access:https://doi.org/10.1038/s41598-025-05697-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-05697-4

Similar Items